Screener
Rhythm Pharmaceuticals, Inc. RYTM Single reportable segment — Other Income (Expense)
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Rhythm Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.
The source filing: Rhythm Pharmaceuticals, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-030549
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Global headcount expense | 58,653 | 34,868 |
| Preclinical, clinical and development expense | 18,511 | 19,960 |
| Commercial & medical affairs | 20,264 | 13,249 |
| Corporate, general & administrative | 7,888 | 7,983 |
| Other income (expense), net | (1,704) | (644) |
| Interest income (expense), net | (1,029) | (1,770) |
| Income taxes | 545 | 80 |
| Net loss | $(55,639) | $(49,498) |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Rhythm Pharmaceuticals, Inc.'s single reportable segment — other income (expense)?
- Rhythm Pharmaceuticals, Inc. (RYTM) reported single reportable segment — other income (expense) of -$1.7M in Q1 2026.
- What does single reportable segment — other income (expense) mean?
- This metric aggregates miscellaneous financial gains or losses that are not directly related to the company's core pharmaceutical operations. It may include items such as currency exchange fluctuations, asset disposals, or other non-operating financial activities. It provides a view into the impact of peripheral financial events on the company's bottom line.
Ask your AI about Rhythm Pharmaceuticals, Inc.'s single reportable segment — other income (expense).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude